With 35 years expertise providing vital cancer research, the Northwell Health Cancer Institute is applying to continue as a community site for the National Cancer Institute Community Oncology Research Program (NCORP). Cancer has been identified as a high priority in our catchment area and, through affiliations with the various NCORP Research bases, our site is able to bring cancer clinical research to the populations in our community. In alignment with NCORP goals, the Northwell Health NCORP will continue to: 1. provide patients access to national cancer control, prevention, treatment, and care delivery studies, 2. engage with underrepresented populations to reduce health disparities and increase health equity, and 3. identify significant concerns raised by our unique local populations. As the program continues, our community site will enhance relationships with all Northwell Health Divisions and strengthen communication between primary and sub- affiliate sites. The Northwell Health Cancer Institute, including 9 NCORP performance site, is a multi-faceted program which treats approximately 14,000 patients with cancer annually. Since the inception of the new NCORP in 2014, over 300 patient have been accrued to NCI sponsored trials adding to the broad evidence base which contributed to improved patient outcomes.

Public Health Relevance

The most recent community needs assessment denoted cancer as the most significant health priority in Nassau and Suffolk Counties and the second most significant in Queens County. Strategies to decrease cancer burden were identified and included increased outreach and leveraging education and wellness programs to all communities; diverse, underserved, and anyone in our catchment area. With our current system in place Northwell Health NCORP can affect change on health outcomes in the community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
5UG1CA189850-07
Application #
9990709
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Russo, Sandra
Project Start
2014-08-07
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Feinstein Institute for Medical Research
Department
Type
DUNS #
110565913
City
Manhasset
State
NY
Country
United States
Zip Code
11030
Gounder, Mrinal M; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med 379:2417-2428
Runcie, Karie; Budman, Daniel R; John, Veena et al. (2018) Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics. Mol Med 24:50
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Zent, Clive S; Victoria Wang, Xin; Ketterling, Rhett P et al. (2016) A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). Am J Hematol 91:308-12
Rogers, C Leland; Perry, Arie; Pugh, Stephanie et al. (2016) Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro Oncol 18:565-74
Bhatnagar, B; Blachly, J S; Kohlschmidt, J et al. (2016) Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3). Leukemia 30:1586-9

Showing the most recent 10 out of 20 publications